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ABSTRACT
Streptococcus bovis is being recognised increasingly as a cause of infective endocarditis, and has also been
associated with underlying gastrointestinal malignancy. This study evaluated the molecular epidemi-
ology of S. bovis isolates responsible for endocarditis or bacteraemia in Italian patients between January
1990 and August 2003. S. bovis isolates were classiﬁed on the basis of their biochemical proﬁles,
antimicrobial susceptibilities and genotypes. Of 25 isolates studied, 20 were S. bovis I and ﬁve were
S. bovis II. Seven biochemical proﬁles were identiﬁed. Pulsed-ﬁeld gel electrophoresis (PFGE) analysis
identiﬁed 22 proﬁles that differed by at least two DNA fragments and showed a similarity of < 87%.
Most PFGE patterns represented single isolates that differed in antimicrobial susceptibility, but three
PFGE types were observed, with identical proﬁles and antibiotypes, in isolates from two different
patients. S. bovis I and II isolates grouped into two distinct genetic clusters (I and II) with a similarity
coefﬁcient of 38%. Two sub-clusters (Ia and Ib), with a similarity coefﬁcient of 47%, included 17 S. bovis I
isolates with similar biochemical proﬁles (15 with biotype A, and two with biotype B), but different
resistance phenotypes. Based on the phenotypic and genotypic heterogeneity of the isolates, it is
postulated that the increase in S. bovis endocarditis in this geographical area might have been caused by
the selection of sporadic endemic clones from the endogenous intestinal ﬂora.
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INTRODUCTION
Streptococcus bovis comprises a group of Gram–
positive cocci, belonging to group D of the
Lanceﬁeld classiﬁcation, which are found in the
intestinal ﬂora of 10% of the healthy population,
and in 29–55% of patients with inﬂammatory
bowel disease or colon cancer [1,2]. Recently, the
S. bovis group was the subject of a taxonomic
reappraisal, after which S. bovis I was redesignat-
ed Streptococcus gallolyticus, and S. bovis II ⁄ 1 and
II ⁄ 2 were redesignated Streptococcus lutetiensis and
Streptococcus pasteurianus, respectively [3–5].
However, procedures to identify the new species
accurately have not yet entered into general use.
S. bovis is being recognised increasingly as a
cause of infective endocarditis, and has been
associated with either underlying gastrointestinal
malignancy or severe liver disease as predispo-
sing conditions [6–9]. A signiﬁcant increase in the
prevalence of S. bovis endocarditis has been
observed in the Second University Hospital of
Naples, Italy, which is a referral centre for
infective endocarditis in the Neapolitan area
[10], and similar increases have been observed
elsewhere in southern Europe [6,8,9]. However,
current knowledge regarding S. bovis endocarditis
is incomplete and controversial. The aim of the
present study was to investigate the molecular
epidemiology of S. bovis isolates responsible for
Corresponding author and reprint requests: R. Utili, Unita` di
Medicina Infettivologica e dei Trapianti, Dipartimento di
Scienze Cardiotoraciche e Respiratorie, A. O. Monaldi, Via
L. Bianchi 1, 80131 Naples, Italy
E-mail: riccardo.utili@ospedalemonaldi.it
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
severe infections in patients between January 1990
and August 2003, with the particular aim of
determining whether the increase in the incidence
of S. bovis endocarditis was caused by the spread
of endemic and ⁄ or epidemic S. bovis clones.
MATERIALS AND METHODS
Bacterial isolates
Twenty-ﬁve clinical isolates of S. bovis collected from blood
cultures over a period of 14 years (1990–2003) were investi-
gated. The isolates were from patients in the Neapolitan area
who were admitted to the tertiary referral centre of the Second
University Hospital of Naples, Italy. All isolates were grown
on blood agar plates at 37C and stored at ) 70C in brain–
heart infusion broth containing glycerol 10% v ⁄v. Clinical
diagnosis of infection and ⁄or associated gastrointestinal
pathology was as described previously [10].
Species identiﬁcation and biotyping
Conventional methods (Gram’s stain, catalase test) were used
for initial bacterial identiﬁcation, followed by use of the API 20
Strep system (bioMe´rieux, Marcy l’Etoile, France) for species
determination. API biotypes were deﬁned on the basis of
a-galactosidase, b-glucuronidase and b-galactosidase activity,
and acid production from mannitol, lactose, trehalose, inulin,
rafﬁnose, starch and glycogen.
Antimicrobial susceptibility testing and antibiotyping
Antibiotic susceptibilities were determined with the Kirby–
Bauer disk-diffusion method, according to NCCLS guidelines
[11], for penicillin, levoﬂoxacin, erythromycin, gentamicin,
streptomycin, vancomycin, teicoplanin, linezolid and tetracyc-
line. As breakpoints for aminoglycosides are not yet available
for streptococci, the breakpoints used for gentamicin and
streptomycin were those recommended for staphylococci and
Enterobacteriaceae, respectively. Isolates resistant to genta-
micin or streptomycin by disk-diffusion were re-evaluated
following determination of MICs [12], with interpretation of
MICs according to the published breakpoints for entero-
cocci. Resistance phenotypes were deﬁned on the basis of
differential susceptibilities to levoﬂoxacin, erythromycin,
gentamicin, streptomycin and tetracycline, with a Roman
numeral representing the number of antibiotics to which each
isolate was resistant, and a letter sub-code indicating the
particular combination of antibiotics to which each isolate was
resistant.
Preparation of chromosomal DNA for pulsed-ﬁeld gel
electrophoresis (PFGE) and restriction digestion
Preparation of chromosomal DNA for PFGE was as described
previously [13], with minor modiﬁcations. Brieﬂy, cell sus-
pensions (c. 2 · 109 CFU) were mixed at 50C with an equal
volume of low-melting-point agarose 2% w ⁄v and dispensed
as 20-lL disks that were allowed to solidify at 4C. The cells
contained in the agarose disks were lysed by incubation at
37C overnight in lysis buffer (lysozyme 100 mg ⁄L, RNAse A
50 mg ⁄L and mutanolysin 50 mg ⁄L in 6 mM Tris-HCl, pH 8.0,
1 M NaCl, 100 mM EDTA, sodium deoxycholate 0.2% w ⁄v,
lauroylsarcosine 0.5% w ⁄v), followed by a further overnight
incubation at 50C in proteolysis buffer (proteinase K
1 mg ⁄mL and lauroylsarcosine 1% w ⁄v in 0.5 M EDTA,
pH 8.5). The agarose disks were then washed three times for
10 min each with TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 7.5) and were stored at 4C. When required, the disks were
equilibrated in restriction enzyme buffer for 30 min and then
digested with 40 U ⁄disk of SmaI (New England BioLabs,
Beverly, MA, USA) at 25C for 4 h.
PFGE and analysis of dendrograms
Genomic DNA fragments were separated by PFGE at 14C on
agarose 1% w ⁄v gels in a clamped homogeneous ﬁeld
electrophoresis apparatus (CHEF-DRII system; Bio-Rad,
Hemel Hempstead, UK), with pulse times of 1.2–54 s over
24 h and 6.0 V ⁄ cm. Standards comprising 48.5-kb lambda
concatamers (New England BioLabs) were run as molecular
size markers. The gels were stained with ethidium bromide
(0.5 mg/L) and photographed using standard procedures. The
PFGE proﬁles obtained were converted to TIFF ﬁles and
subjected to cluster analysis using the GelCompare v. 3.5
software package (AppliedMaths, Sint-Martens-Latem,
Belgium). Clustering was based on the unweighted pair-group
method with arithmetic averages (UPGMA). The Dice corre-
lation coefﬁcient was used to analyse the similarities of the
banding patterns [14], with a tolerance of 1%. Isolates with an
identical PFGE banding pattern (similarity coefﬁcient of 100%)
were considered to be isogenic.
RESULTS
Microbial isolates and patients
Of the 25 isolates investigated, 20 were S. bovis I
and ﬁve were S. bovis II. Eighteen S. bovis I isolates
were from blood cultures of patients with endo-
carditis, and two were from patients without
endocarditis. Of the ﬁve S. bovis II isolates, four
were from blood cultures of patients with endo-
carditis, and one was from a patient without
endocarditis. The epidemiological and clinical
characteristics of these patients are summarised
in Table 1. Of the 22 patients with endocarditis, 18
(72%) had presented in the last 4 years. Seventeen
were male and the median age was 59.5 years
(range 21–77 years). Endocarditis involved native
valves in 20 patients and a prosthetic valve in two
patients (Table 1). Chronic liver disease was
observed in 11 of 20 and one of ﬁve patients with
S. bovis I and S. bovis II, respectively. Eighteen
patients with S. bovis I underwent colonoscopy;
colon adenomas were found in seven patients and
colon cancer in one. Of the ﬁve patients with S.
bovis II, two had colon adenoma, and one had anal
rhagades. No underlying clinical conditions were
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observed in four patients (three with S. bovis I,
and one with S. bovis II) (Table 1).
API biotyping
The S. bovis isolates were classiﬁed into seven
distinct biotypes on the basis of their biochemical
proﬁles (Table 1). Fifteen S. bovis I isolates
belonged to biotype A, with the presence of
a-galactosidase, the absence of b-glucuronidase
and b-galactosidase, and acid production from
mannitol, lactose, trehalose, inulin, rafﬁnose,
starch and glycogen. Four isolates belonged to
biotype B, which differed from biotype A by the
absence of a-galactosidase activity. One isolate
belonged to biotype C, which differed from
biotype A by the absence of acid production from
inulin. The ﬁve isolates of S. bovis II belonged to
biotypes D–G, with the following proﬁles: biotype
D (n = 1), presence of a-galactosidase, absence of
b-glucuronidase and b-galactosidase, acid pro-
duction from rafﬁnose and starch, absence of acid
production from mannitol, lactose, trehalose,
inulin and glycogen; biotype E (n = 2), presence
of a-galactosidase, b-glucuronidase and b-galac-
tosidase, acid production from lactose, trehalose
and rafﬁnose, absence of acid production from
mannitol, inulin, starch and glycogen; biotype F
(n = 1), presence of a-galactosidase and b-glucu-
ronidase, absence of b-galactosidase, acid pro-
duction from lactose, trehalose and rafﬁnose,
absence of acid production from mannitol, inulin,
starch and glycogen; and biotype G (n = 1),
presence of b-glucuronidase and b-galactosidase,
absence of a-galactosidase, acid production from
lactose and trehalose, absence of acid production
from mannitol, inulin, rafﬁnose, starch and gly-
cogen. API biotyping was repeated three times,
with the same results being obtained on each
occasion. On the basis of the biochemical reac-
tions, the 20 S. bovis I isolates were identiﬁed as
S. gallolyticus [3,4], and one S. bovis II ⁄ 1 and four
S. bovis II ⁄ 2 isolates were identiﬁed as S. lutetiensis
and S. pasteurianus, respectively [3,5].
Antibiotic susceptibility studies and
antibiotyping
All 25 isolates were susceptible to penicillin,
glycopeptides and linezolid. One (4%) isolate
was resistant to levoﬂoxacin, 12 (48%) to eryth-
romycin, two (8%) to gentamicin, 18 (69%) to
Table 1. Clinical, phenotypic and genotypic characteristics of Streptococcus bovis isolates in this study
Isolate Pathogena Month/year Diagnosis Valve involvement Underlying disease API biotypeb
Resistance phenotypec
PFGE typed ClusterdLE E GM SM TE Phenotype
1361 S. bovis I 10 ⁄ 01 END Mitral Advanced adenoma A S S S S S 0 1 Ia
1365 S. bovis I 11 ⁄ 01 END Tricuspid Advanced adenoma A S S S S S 0 1 Ia
1355 S. bovis I 9 ⁄ 01 END Aortic + mitral HCV cirrhosis ⁄Hepatocarcinoma A S R S R* S II 2 Ia
1459 S. bovis I 7 ⁄ 03 END Aortic + mitral Advanced adenoma ⁄HCV hepatitis A S R S R R III 3 Ia
1151 S. bovis I 5 ⁄ 98 END Aortic + mitral None A S S S R R IIa 4 Ia
609 S. bovis I 11 ⁄ 92 END Mitral HCV and alcoholic cirrhosis B S R S R* R III 5 Ia
1212 S. bovis I 3 ⁄ 99 END Aortic Adenoma A S S S R S I 6 Ia
1293 S. bovis I 6 ⁄ 00 END Aortic + mitral None A S S S R S I 6 Ia
1260 S. bovis I 2 ⁄ 00 END Aortic + mitral HCV ﬁbrosis A S R S R* R III 7 Ia
887 S. bovis I 12 ⁄ 94 Bacteraemia None Bladder cancer A S R R R S IIIa 8 Ib
1376 S. bovis I 2 ⁄ 02 END Aortic Cryptogenic cirrhosis A S S S R R IIa 9 Ib
1467 S. bovis I 8 ⁄ 03 END Mitral HCV chronic hepatitis B S R S S R IIb 10 Ib
1417 S. bovis I 12 ⁄ 02 END Mitral prosthesis Adenoma A S S S R R IIa 11 Ib
1445 S. bovis I 5 ⁄ 03 END Aortic Colon cancer ⁄Alcoholic cirrhosis A S S S R R IIa 11 Ib
1386 S. bovis I 5 ⁄ 02 END Aortic HCV chronic hepatitis A S S S S R Ia 12 Ib
225 S. bovis I 5 ⁄ 90 Bacteraemia None None B S S S R R IIa 13 Ib
848 S. bovis I 9 ⁄ 94 END Aortic + mitral HCV cirrhosis B S R R R* S IIIa 14 Ib
1294 S. bovis I 6 ⁄ 00 END Aortic Advanced adenoma ⁄HCV ﬁbrosis A S S S S S 0 15 I
1364 S. bovis I 10 ⁄ 01 END Aortic + mitral Adenoma C S S S R R IIa 16 I
1439 S. bovis I 4 ⁄ 03 END Aortic HBV cirrhosis A S S S S S 0 17 I
1067 S. bovis II ⁄ 1 1 ⁄ 97 Bacteraemia None HCV cirrhosis D R R S S R IIIb 18 II
1374 S. bovis II ⁄ 2 2 ⁄ 02 END Aortic Anal rhagades F S R S R R III 19 II
207 S. bovis II ⁄ 2 3 ⁄ 90 END Aortic Adenoma G S R S R R III 20 II
1440 S. bovis II ⁄ 2 4 ⁄ 03 END Aortic None E S R S R R III 21 II
992 S. bovis II ⁄ 2 11 ⁄ 95 END Aortic prosthesis Advanced adenoma E S R S R R III 22 II
END, endocarditis; HCV, hepatitis C virus; PFGE, pulsed-ﬁeld gel electrophoresis; LE, levoﬂoxacin; E, erythromycin; GM, gentamicin; SM, streptomycin; TE, tetracycline;
S, susceptible; R, resistant; R*, high-level resistant.
aIdentiﬁcation and biotype assignment was performed using the API 20 Strep system.
bAPI biotypes were deﬁned on the basis of differential biochemical proﬁles of the strains as described in ‘Materials and methods’.
cResistance phenotypes were deﬁned on the basis of differential susceptibility of each isolate to the ﬁve selected antimicrobial agents shown in the table, with Roman numerals
representing the number of antibiotics to which each isolate was resistant, and a letter sub-code indicating the particular combination of antibiotics to which each isolate was
resistant.
dSee legend to Fig. 1 and main text for details.
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streptomycin, and 16 (64%) to tetracycline. More-
over, four (22.2%) of the 18 streptomycin-resistant
isolates showed high-level resistance
(MIC > 1000 mg ⁄L). No high-level resistance
was observed for gentamicin. Nine antibiotypes
were identiﬁed: four isolates were susceptible;
three were resistant to one antibiotic; eight were
resistant to two antibiotics; and ten were resistant
to three antibiotics (Table 1).
Genotyping
Twenty-two major PFGE types, designated 1–22,
were identiﬁed. These differed in the migration of
at least two DNA fragments and showed a simi-
larity of < 87%. Most isolates had unique PFGE
patterns, but PFGE types 1, 6 and 11 were each
observed in isolates from two different patients
(Fig. 1), separated by 1, 15 and 6 months, respect-
ively (Table 1). The two patients who yielded
isolates of PFGE type 1were already infected at the
time of hospital admission, which excludes the
possibility of nosocomial cross-transmission.
The dendrogram analysis showed two major
clusters with a similarity coefﬁcient of < 38%,
with cluster I containing all the S. bovis I isolates,
and cluster II containing the S. bovis II isolates.
Two sub-clusters (Ia and Ib), containing nine and
eight S. bovis I isolates, respectively, were identi-
ﬁed with a similarity coefﬁcient of 47% (Fig. 1).
Of 17 S. bovis I isolates included in sub-clusters Ia
and Ib, 15 had API biotype proﬁle A, while two
had API biotype proﬁle B (Table 1). The isolates
with identical PFGE proﬁles (1, 6 and 11) had
identical antibiotypes (0, I and IIa, respectively;
Table 1).
DISCUSSION
The sudden increase in cases of S. bovis endocar-
ditis that has been observed in recent years in
southern Europe [9,10] has not been reported in
the USA and Australia, and the reasons for this
increase are still unknown. The present study
investigated the microbiological and genotypic



























































































Fig. 1. Genotypic analysis of 25 digitised SmaI PFGE proﬁles of Streptococcus bovis isolates. Genotypes are indicated by
Arabic numerals, while clusters and sub-clusters (cut-off values of 38% and 47% similarity, respectively) are indicated by
Roman numerals.
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severe infections in patients seen in our institution
during the last 15 years; 72% of these isolates
were obtained in the last 4 years. In total, 20 of 25
isolates were S. bovis I, which is in agreement with
a recent report that most (78%) S. bovis endocar-
ditis isolates were S. bovis biotype I [15], whereas
S. bovis biotype II seemed to predominate in
isolates causing sepsis [16,17]. Interestingly, endo-
carditis caused by S. bovis I, which is observed
increasingly in patients from this area [10], is
associated signiﬁcantly with both chronic liver
disease (58% in this series) and colonic adenomas
(37%) [1,2]. Also, in agreement with previous
data [10], S. bovis endocarditis involves native
valves, with a high rate (32%) of bivalvular
involvement, in the absence of previously identi-
ﬁed valve abnormalities.
Although S. bovis isolates in the present study
could be grouped into two genetic clusters con-
taining S. bovis I and II isolates, respectively, there
was considerable diversity between isolates, with
most isolates having unique PFGE proﬁles. Simi-
larly, a previous study demonstrated that eight
S. bovis blood isolates from eight patients had
different PFGE proﬁles, while two isolates from
the same patient, 8 years apart, had identical
PFGE proﬁles [18]. Other studies have shown that
S. bovis isolates cluster in three different geno-
types by 16S ribosomal DNA sequence analysis,
comprising S. bovis biotype I, and S. bovis biotypes
II ⁄ 1 and II ⁄ 2 [16,17]. Discrepancies between the
results of these studies might be related to the
different typing methods used.
Notwithstanding the heterogeneity of the PFGE
proﬁles, PFGE types 1, 6 and 11 were each
observed in isolates from two patients, and were
included in two sub-clusters (Ia and Ib) contain-
ing nine and eight S. bovis I isolates, respectively.
Most (14 ⁄ 17) of these isolates were obtained
during a relatively short interval, suggesting a
possible temporal relationship with the circula-
tion of selected pathogenic strains in the commu-
nity. Common virulence factors might have been
responsible for their selection from the total
microbial population.
Antimicrobial typing of the S. bovis isolates
provided additional epidemiological information.
Several isolates were characterised by resistance
to erythromycin, tetracycline or streptomycin;
four isolates showed high-level resistance to
streptomycin. In particular, S. bovis II isolates
showed a more resistant phenotype than S. bovis I
isolates, as all were resistant to erythromycin and
tetracycline, and four of the ﬁve isolates were also
resistant to streptomycin. Previous studies have
shown that c. 70% of S. bovis II isolates from
patients in Taiwan [19] and Hong Kong [17] have
high-level resistance to erythromycin, and indu-
cible or constitutive resistance to macrolide–
lincosamide–streptogramin B antibiotics. The
present study identiﬁed nine different antibio-
types among the S. bovis isolates (Table 1). A
partial correlation was found between genotype,
as assessed by PFGE, and the resistance pheno-
type. S. bovis isolates with identical PFGE proﬁles
(types 1, 6 and 11) had identical antimicrobial
resistance proﬁles, but some isolates with an
identical antibiotype had different PFGE proﬁles
(Table 1), thus reinforcing the hypothesis that
S. bovis isolates in this area have an elevated
heterogeneity.
In conclusion, the data from this study exclude
the selection of a single epidemic clone of S. bovis,
and suggest that sporadic clones have been
selected from the endogenous intestinal microﬂo-
ra. Determination of whether these clones share
common genetic traits and have a common origin
will require further studies involving larger series
of patients, with isolates from different European
countries.
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